Edwards Lifesciences

Edwards Lifesciences Corporation is a premier American medical technology company headquartered in Irvine, California, that has revolutionized the treatment of structural heart disease through innovative medical devices and therapies. Founded on the pioneering work of Miles Lowell Edwards and Dr. Albert Starr in the late 1950s, the company has grown from developing the world's first successful artificial heart valve to becoming the global leader in transcatheter heart valve replacement and repair technologies.

Spun off from Baxter International in 2000, Edwards Lifesciences has established itself as a pure-play structural heart company following its strategic divestiture of the Critical Care business to BD for $4.2 billion in 2024. The company's product portfolio centers on four main categories: Transcatheter Aortic Valve Replacement (TAVR) through its industry-leading SAPIEN family of valves, Surgical Structural Heart solutions including the INSPIRIS RESILIA valve, Transcatheter Mitral and Tricuspid Therapies (TMTT) featuring the PASCAL and Cardioband systems, and historically, Critical Care monitoring products.

Edwards Lifesciences commands an impressive market position, controlling approximately 60% of the global TAVR market and over 70% in the United States, significantly outpacing competitors like Medtronic (28% worldwide, 24% US) and emerging players such as Abbott and Boston Scientific. The company generated $5.44 billion in revenue for fiscal year 2024, representing 8.6% growth year-over-year, with a market capitalization of $43.4 billion and approximately 15,800 employees worldwide. The company's TAVR business remains the primary revenue driver, while its TMTT segment experienced explosive 88% growth in Q4 2024, reaching $105 million in sales.

With over 60 years of cardiovascular innovation, Edwards Lifesciences continues to push the boundaries of medical technology through strategic acquisitions and internal research and development. Recent 2024 acquisitions include JenaValve Technology and Endotronix for a combined $1.2 billion, positioning the company to address aortic regurgitation and heart failure management—two significant unmet clinical needs. The company's commitment to transforming patient care through breakthrough medical technologies, combined with its strong financial performance and market leadership, solidifies its position as a cornerstone of the modern cardiovascular medical device industry.